Loading...

TransEnterix Provides Corporate Update

October 01, 2018 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today provided a corporate update, including preliminary unaudited revenue for the third quarter ended September 30, 2018. “We made significant progress during the third quarter, including

By |2018-10-01T21:28:53+00:00October 1st, 2018|Financial|

Spineology U.S. Clinical Trial for Interbody Fusion

October 01, 2018 ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology Inc., an innovator in anatomy-conserving spine surgery, is excited to announce that John Chi, M.D., M.P.H., Associate Professor of Neurosurgery at Harvard Medical School and the Director of Neurosurgical Spinal Oncology at Brigham and Women’s Hospital in Boston, Massachusetts, presented 12-month outcomes data from Spineology’s SCOUT clinical trial

By |2018-10-01T16:58:51+00:00October 1st, 2018|Spine|

Medacta International Appoints Francesco Siccardi its Next Chief Executive Officer

October 01, 2018 CASTEL SAN PIETRO, Switzerland--(BUSINESS WIRE)--Medacta® International, the privately held, family-owned global leader in the design of innovative joint replacement and spinal surgery products, today announced that Francesco Siccardi, a noted biomedical engineer and current Executive Vice President of Medacta International, will become the company’s next chief executive officer on November 1, 2018. After

By |2018-10-01T15:07:13+00:00October 1st, 2018|Recon|

TransEnterix Receives CE Mark Approval for Senhance Ultrasonic Instrument System

October 01, 2018 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Company received CE Mark approval for its Senhance Ultrasonic Instrument System. Advanced energy devices, including ultrasonic devices, represent some of

By |2018-10-01T14:51:36+00:00October 1st, 2018|Regulatory|

Safe Orthopaedics’ Continues to Improve Results over the First Six Months of 2018

September 28, 2018 ERAGNY-SUR-OISE, France--(BUSINESS WIRE)--Regulatory News: SAFE ORTHOPAEDICS (FR0012452746 – SAFOR) (Paris:SAFOR), Safe Orthopaedics (FR0012452746 – SAFOR), a company specialized in the development and marketing of implants and single-use instruments that improve the minimally invasive treatment of spinal fracture conditions, today announced its revenue for the six-month period ending on the 30th June 2018. Safe Orthopaedics’

By |2018-09-28T22:42:57+00:00September 28th, 2018|Financial|

Renovis Surgical Receives FDA Clearance for Tesera Trabecular Technology 3D-Printed Lateral Interbody Fusion System

REDLANDS, Calif. and AUSTIN, Texas, Sept. 26, 2018 /PRNewswire/ -- Renovis Surgical Technologies, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Tesera® X Lateral Interbody Fusion System. Tesera X is the latest product to utilize Renovis' proprietary 3D-printed porous architecture, which is made using additively manufactured titanium alloy, and

By |2018-09-28T22:26:34+00:00September 28th, 2018|Regulatory, Top Stories|

4WEB Medical, TeDan Surgical Innovations and Lattus Spine Announce Exclusive Partnership To Provide Best In Class Total Lateral Solution

LOS ANGELES, Sept. 26, 2018 /PRNewswire/ -- 4WEB Medical, the industry leader in 3D printed implant technology, announced today at the North American Spine Society (NASS) Annual Meeting that the company has entered into an exclusive partnership with both TeDan Surgical Innovations and Lattus Spine, LLC to market a turnkey, best in class, Total Lateral Solution. "Today is

By |2018-09-27T22:59:14+00:00September 27th, 2018|Spine|

Stryker announces 510(k) clearance of SpineJack® Implantable Fracture Reduction System

KALAMAZOO, Michigan, USA, Sept. 26, 2018 /PRNewswire/ -- Stryker announced today that it has received FDA 510(k) clearance to market the SpineJack Implantable Fracture Reduction System.  The SpineJack system is indicated for use in the reduction of painful osteoporotic vertebral compression fractures. In the SAKOS clinical study, the SpineJack system demonstrated superiority to balloon kyphoplasty (BKP) for the

By |2018-09-27T22:22:18+00:00September 27th, 2018|Regulatory, Spine|

Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

WALTHAM, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today announced that the U.S. Food and Drug Administration (the FDA) has granted a Type C meeting on October 30, 2018 to discuss the

By |2018-09-27T18:15:46+00:00September 27th, 2018|Regulatory|

Kuros Reports First Patient Treated in Randomized Controlled Trial of MagnetOs in Spinal Fusion

SCHLIEREN (ZURICH), Switzerland, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced that the first patient has been treated in an investigator-led multicenter randomized controlled study comparing MagnetOs with autologous bone in posterolateral spinal fusion. The University Medical Center Utrecht (UMCU) in the Netherlands is the principal investigating site for the study,

By |2018-09-27T17:38:49+00:00September 27th, 2018|Spine|